Search for: All records

Machine learning models exhibit strong performance on datasets with abundant labeled samples. However, for tabular datasets with extremely high d-dimensional features but limited n samples (i.e. d ≫ n), machine learning models struggle to achieve strong performance due to the risk of overfitting. Here, our key insight is that there is often abundant, auxiliary domain information describing input features which can be structured as a heterogeneous knowledge graph (KG). We propose PLATO, a method that achieves strong performance on tabular data with d ≫ n by using an auxiliary KG describing input features to regularize a multilayer perceptron (MLP). In PLATO, each input feature corresponds to a node in the auxiliary KG. In the MLP’s first layer, each input feature also corresponds to a weight vector. PLATO is based on the inductive bias that two input features corresponding to similar nodes in the auxiliary KG should have similar weight vectors in the MLP’s first layer. PLATO captures this inductive bias by inferring the weight vector for each input feature from its corresponding node in the KG via a trainable message-passing function. Across 6 d ≫ n datasets, PLATO outperforms 13 state-of-the-art baselines by up to 10.19%. 

Abstract Most diseases disrupt multiple proteins, and drugs treat such diseases by restoring the functions of the disrupted proteins. How drugs restore these functions, however, is often unknown as a drug’s therapeutic effects are not limited to the proteins that the drug directly targets. Here, we develop the multiscale interactome, a powerful approach to explain disease treatment. We integrate disease-perturbed proteins, drug targets, and biological functions into a multiscale interactome network. We then develop a random walk-based method that captures how drug effects propagate through a hierarchy of biological functions and physical protein-protein interactions. On three key pharmacological tasks, the multiscale interactome predicts drug-disease treatment, identifies proteins and biological functions related to treatment, and predicts genes that alter a treatment’s efficacy and adverse reactions. Our results indicate that physical interactions between proteins alone cannot explain treatment since many drugs treat diseases by affecting the biological functions disrupted by the disease rather than directly targeting disease proteins or their regulators. We provide a general framework for explaining treatment, even when drugs seem unrelated to the diseases they are recommended for.